carboprost 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| prostaglandins | 502 | 35700-23-3 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A nonsteroidal abortifacient agent that is effective in both the first and second trimesters of PREGNANCY.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 2.50 | mg | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.47 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| S (Water solubility) | 75 mg/mL | Bocci G, Oprea TI, Benet LZ |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Bocci G, Oprea TI, Benet LZ |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Jan. 9, 1979 | FDA | PHARMACIA AND UPJOHN |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | G02AD04 | GENITO URINARY SYSTEM AND SEX HORMONES OTHER GYNECOLOGICALS UTEROTONICS Prostaglandins |
| FDA CS | M0017805 | Prostaglandins |
| FDA EPC | N0000175454 | Prostaglandin Analog |
| CHEBI has role | CHEBI:36063 | oxytocic agents |
| CHEBI has role | CHEBI:50691 | abortifacient drug |
| MeSH PA | D010120 | Oxytocics |
| MeSH PA | D012102 | Reproductive Control Agents |
| MeSH PA | D000019 | Abortifacient Agents |
| MeSH PA | D000020 | Abortifacient Agents, Nonsteroidal |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Postpartum hemorrhage | indication | 47821001 | |
| Pregnancy with abortive outcome | indication | 363681007 | |
| Incomplete miscarriage | off-label use | 156072005 | |
| Induction of labor | off-label use | 236958009 | |
| Cervical ripening procedure | off-label use | 236959001 | |
| Hydatidiform mole, benign | off-label use | 417044008 | |
| Hyperbilirubinemia | contraindication | 14783006 | DOID:2741 |
| Disorder of lung | contraindication | 19829001 | DOID:850 |
| Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
| Mild pre-eclampsia | contraindication | 41114007 | |
| Third trimester pregnancy | contraindication | 41587001 | |
| Low blood pressure | contraindication | 45007003 | |
| Severe pre-eclampsia | contraindication | 46764007 | |
| Heart disease | contraindication | 56265001 | DOID:114 |
| Acute nephropathy | contraindication | 58574008 | |
| Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
| Stenosis of cervix | contraindication | 83536006 | |
| Epilepsy | contraindication | 84757009 | DOID:1826 |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Asthma | contraindication | 195967001 | DOID:2841 |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Anemia | contraindication | 271737000 | DOID:2355 |
| Gynecological Surgery | contraindication | ||
| Inflammatory Disease of Female Pelvic Organs | contraindication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 4.79 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Prostaglandin F2-alpha receptor | GPCR | AGONIST | CHEMBL | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4018095 | VUID |
| N0000146433 | NUI |
| D00682 | KEGG_DRUG |
| 58551-69-2 | SECONDARY_CAS_RN |
| 20259 | RXNORM |
| C0007047 | UMLSCUI |
| CHEBI:3403 | CHEBI |
| CHEMBL1237122 | ChEMBL_ID |
| CHEMBL1237105 | ChEMBL_ID |
| D002260 | MESH_DESCRIPTOR_UI |
| C062843 | MESH_SUPPLEMENTAL_RECORD_UI |
| 5281075 | PUBCHEM_CID |
| 4044 | INN_ID |
| 7B5032XT6O | UNII |
| DB00429 | DRUGBANK_ID |
| 319432 | MMSL |
| 4358 | MMSL |
| d00588 | MMSL |
| 109057004 | SNOMEDCT_US |
| 109058009 | SNOMEDCT_US |
| 373455002 | SNOMEDCT_US |
| 4018095 | VANDF |
| 4022193 | VANDF |
| 001310 | NDDF |
| 004942 | NDDF |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Hemabate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0009-0856 | INJECTION, SOLUTION | 250 ug | INTRAMUSCULAR | NDA | 19 sections |
| Carboprost Tromethamine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43598-698 | INJECTION, SOLUTION | 250 ug | INTRAMUSCULAR | ANDA | 15 sections |
| CARBOPROST TROMETHAMINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43598-917 | INJECTION, SOLUTION | 250 ug | INTRAMUSCULAR | ANDA | 15 sections |
| CARBOPROST TROMETHAMINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43598-919 | INJECTION, SOLUTION | 250 ug | INTRAMUSCULAR | ANDA | 15 sections |
| CARBOPROST TROMETHAMINE | Human Prescription Drug Label | 1 | 55150-459 | INJECTION, SOLUTION | 250 ug | INTRAMUSCULAR | ANDA | 10 sections |
| CARBOPROST TROMETHAMINE | Human Prescription Drug Label | 1 | 62332-777 | INJECTION, SOLUTION | 250 ug | INTRAMUSCULAR | ANDA | 10 sections |
| CARBOPROST TROMETHAMINE | Human Prescription Drug Label | 1 | 65145-132 | INJECTION, SOLUTION | 250 ug | INTRAMUSCULAR | ANDA | 15 sections |
| CARBOPROST TROMETHAMINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65219-579 | INJECTION, SOLUTION | 250 ug | INTRAMUSCULAR | ANDA | 15 sections |
| carboprost tromethamine | Human Prescription Drug Label | 1 | 68083-584 | INJECTION, SOLUTION | 250 ug | INTRAMUSCULAR | ANDA | 16 sections |
| CARBOPROST TROMETHAMINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69784-240 | INJECTION, SOLUTION | 250 ug | INTRAMUSCULAR | ANDA | 19 sections |
| CARBOPROST TROMETHAMINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69784-240 | INJECTION, SOLUTION | 250 ug | INTRAMUSCULAR | ANDA | 19 sections |
| CARBOPROST TROMETHAMINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69784-240 | INJECTION, SOLUTION | 250 ug | INTRAMUSCULAR | ANDA | 19 sections |
| carboprost tromethamine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70121-1680 | INJECTION, SOLUTION | 250 ug | INTRAMUSCULAR | ANDA | 15 sections |
| carboprost tromethamine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70512-859 | INJECTION, SOLUTION | 250 ug | INTRAMUSCULAR | ANDA | 19 sections |
| CARBOPROST TROMETHAMINE | Human Prescription Drug Label | 1 | 71839-137 | INJECTION, SOLUTION | 250 ug | INTRAMUSCULAR | ANDA | 9 sections |
| Carboprost Tromethamine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 81298-5010 | INJECTION | 250 ug | INTRAMUSCULAR | ANDA | 18 sections |
| Carboprost Tromethamine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 81298-5010 | INJECTION | 250 ug | INTRAMUSCULAR | ANDA | 18 sections |